Livforsakringsbolaget Skandia’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $126K | Hold |
1,000
| – | – | 0.01% | 461 |
|
|
2025
Q1 | $111K | Hold |
1,000
| – | – | 0.01% | 488 |
|
|
2024
Q4 | $137K | Sell |
1,000
-2,800
| -74% | -$382K | 0.01% | 462 |
|
|
2024
Q3 | $437K | Buy |
3,800
+800
| +27% | +$92.1K | 0.02% | 297 |
|
|
2024
Q2 | $413K | Hold |
3,000
| – | – | 0.03% | 203 |
|
|
2024
Q1 | $413K | Hold |
3,000
| – | – | 0.04% | 206 |
|
|
2023
Q4 | $395K | Buy |
3,000
+1,100
| +58% | +$145K | 0.04% | 207 |
|
|
2023
Q3 | $214K | Hold |
1,900
| – | – | 0.02% | 229 |
|
|
2023
Q2 | $179K | Hold |
1,900
| – | – | 0.02% | 240 |
|
|
2023
Q1 | $192K | Hold |
1,900
| – | – | 0.02% | 244 |
|
|
2022
Q4 | $227K | Hold |
1,900
| – | – | 0.03% | 241 |
|
|
2022
Q3 | $201K | Sell |
1,900
-600
| -24% | -$63.5K | 0.02% | 246 |
|
|
2022
Q2 | $244K | Sell |
2,500
-400
| -14% | -$39K | 0.02% | 307 |
|
|
2022
Q1 | $272K | Hold |
2,900
| – | – | 0.02% | 399 |
|
|
2021
Q4 | $247K | Buy |
2,900
+1,700
| +142% | +$145K | 0.02% | 454 |
|
|
2021
Q3 | $115K | Hold |
1,200
| – | – | 0.01% | 582 |
|
|
2021
Q2 | $117K | Hold |
1,200
| – | – | 0.01% | 599 |
|
|
2021
Q1 | $117K | Hold |
1,200
| – | – | 0.01% | 575 |
|
|
2020
Q4 | $115K | Hold |
1,200
| – | – | 0.01% | 564 |
|
|
2020
Q3 | $115K | Hold |
1,200
| – | – | 0.01% | 509 |
|
|
2020
Q2 | $146K | Buy |
1,200
+500
| +71% | +$60.8K | 0.02% | 440 |
|
|
2020
Q1 | $61K | Hold |
700
| – | – | 0.01% | 572 |
|
|
2019
Q4 | $75K | Buy |
+700
| New | +$75K | 0.01% | 579 |
|